Hiroto Ohguchi

Dr. Hiroto Ohguchi

Kumamoto University, Kumamoto, Japan
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2018 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
HOHiroto Ohguchi
Hiroto Ohguchi
THTeru Hideshima
Teru Hideshima
KAKenneth Anderson
Kenneth Anderson
Multiple myeloma (MM) is a clonal plasma cell disorder that is characterized by a variety of genetic alterations. Recent studies have highlighted not only the importance of these genetic events but also epigenetic aberrations including DNA methylation, histone modifications, and non-coding RNAs in the biology of MM. Post-translational modifications of histone, such as methylation and acetylation, contribute to chromatin dynamics, and are modulated by histone modifying enzymes, and dysregulation of these enzymes is implicated in the pathogenesis of cancers, including MM. Histone modifiers also have non-histone substrates and enzymatically independent roles, which are also involved in tumorigenesis. Here we review and provide comprehensive insight into the biologic significance of histone methyl- and acetyl-modifiers in MM, and further provide an overview of the clinical applications of histone modifier inhibitors, especially histone deacetylase inhibitors. These findings underline the emerging roles of histone modifiers in the pathogenesis of MM, and further highlight the possibility of novel epigenetic therapies in MM.

4 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
YOYasuyo Ohguchi
Yasuyo Ohguchi
HOHiroto Ohguchi
Hiroto Ohguchi
Epigenetic modifications are crucial for chromatin remodeling and transcriptional regulation. Post-translational modifications of histones are epigenetic processes that are fine-tuned by writer and eraser enzymes, and the disorganization of these enzymes alters the cellular state, resulting in human diseases. The KDM5 family is an enzymatic family that removes di- and tri-methyl groups (me2 and me3) from lysine 4 of histone H3 (H3K4), and its dysregulation has been implicated in cancer. Although H3K4me3 is an active chromatin marker, KDM5 proteins serve as not only transcriptional repressors but also transcriptional activators in a demethylase-dependent or -independent manner in different contexts. Notably, KDM5 proteins regulate the H3K4 methylation cycle required for active transcription. Here, we review the recent findings regarding the mechanisms of transcriptional regulation mediated by KDM5 in various contexts, with a focus on cancer, and further shed light on the potential of targeting KDM5 for cancer therapy.

10 April 2021 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
HOHiroto Ohguchi
Hiroto Ohguchi
PPPaul M.C. Park
Paul M.C. Park
TWTingjian Wang
Tingjian Wang
BGBerkley Gryder
Berkley Gryder
DODaisuke Ogiya
Daisuke Ogiya
JQJun Qi
Jun Qi
Lysine demethylase 5A (KDM5A) is a negative regulator of histone H3 lysine 4 trimethy­lation (H3K4me3), a histone mark associated with activate gene transcription. We identify that KDM5A interacts with the P-TEFb complex and cooperates with MYC to control MYC-targeted genes in multiple myeloma cells. We develop a cell-permeable and selective KDM5 inhibitor, JQKD82, that increases H3K4me3 but paradoxically inhibits downstream MYC-driven transcriptional output in vitro and in vivo. Using genetic ablation together with our inhibitor, we establish that KDM5A supports MYC target gene transcription independent of MYC itself by supporting TFIIH (CDK7)- and P-TEFb (CDK9)–mediated phosphorylation of RNAPII. These data identify KDM5A as a unique vulnerability in multiple myeloma functioning through regulation of MYC target gene transcription and establish JQKD82 as a tool compound to block KDM5A function as a potential therapeutic strategy for multiple myeloma. Significance: We delineate the function of KDM5A in activating the MYC-driven transcriptional landscape. We develop a cell-permeable KDM5 inhibitor to define the activating role of KDM5A on MYC target gene expression and implicate the therapeutic potential of this compound in mouse models and multiple myeloma patient samples. See related video from the AACR Annual Meeting 2021: https://vimeo.com/554896826

Verified
Journal Article
Open access
PDF file
YOYasuyo Ohguchi
Yasuyo Ohguchi
HOHiroto Ohguchi
Hiroto Ohguchi
Recent studies have revealed the genetic aberrations involved in the initiation and progression of various cancers, including multiple myeloma (MM), via next-generation sequencing analysis. Notably, DIS3 mutations have been identified in approximately 10% of patients with MM. Moreover, deletions of the long arm of chromosome 13, that includes DIS3, are present in approximately 40% of patients with MM. Regardless of the high incidence of DIS3 mutations and deletions, their contribution to the pathogenesis of MM has not yet been determined. Herein, we summarize the molecular and physiological functions of DIS3, focusing on hematopoiesis, and discuss the characteristics and potential roles of DIS3 mutations in MM. Recent findings highlight the essential roles of DIS3 in RNA homeostasis and normal hematopoiesis and suggest that the reduced activity of DIS3 may be involved in myelomagenesis by increasing genome instability.

20 March 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
THTakeshi Harada
Takeshi Harada
HOHiroto Ohguchi
Hiroto Ohguchi
AOAsuka Oda
Asuka Oda
MNMichiyasu Nakao
Michiyasu Nakao
JTJumpei Teramachi
Jumpei Teramachi
MAMasahiro Abe
Masahiro Abe
Multiple myeloma (MM) preferentially expands and acquires drug resistance in the bone marrow (BM). We herein examined the role of histone deacetylase 1 (HDAC1) in the constitutive activation of the master transcription factor IRF4 and the prosurvival mediator PIM2 kinase in MM cells. The knockdown or inhibition of HDAC1 by the class I HDAC inhibitor MS-275 reduced the basal expression of IRF4 and PIM2 in MM cells. Mechanistically, the inhibition of HDAC1 decreased IRF4 transcription through histone hyperacetylation and inhibiting the recruitment of RNA polymerase II at the IRF4 locus, thereby reducing IRF4-targeting genes, including PIM2. In addition to the transcriptional regulation of PIM2 by the HDAC1-IRF4 axis, PIM2 was markedly upregulated by external stimuli from BM stromal cells and interleukin-6 (IL-6). Upregulated PIM2 contributed to the attenuation of the cytotoxic effects of MS-275. Class I HDAC and PIM kinase inhibitors cooperatively suppressed MM cell growth in the presence of IL-6 and in vivo. Therefore, the present results demonstrate the potential of the simultaneous targeting of the intrinsic HDAC1-IRF4 axis plus externally activated PIM2 as an efficient therapeutic option for MM fostered in the BM.

2 June 2026 in Blood Advances
Verified
Journal Article
Open access
PDF file
YOYasuyo Ohguchi
Yasuyo Ohguchi
MAMasahiko Ajiro
Masahiko Ajiro
DODaisuke Ogiya
Daisuke Ogiya
TMTakeshi Masuda
Takeshi Masuda
YKYawara Kawano
Yawara Kawano
HOHiroto Ohguchi
Hiroto Ohguchi
Multiple myeloma (MM) is a plasma cell neoplasm that depends on the bone marrow (BM) microenvironment; however, the underlying mechanisms of epigenetic contribution to the pathogenesis of MM are incompletely understood. Here, we delineate epigenetically driven transcriptional and splicing regulation crucial for MM. We recharacterized the transcriptional program induced by interleukin 6 (IL-6)/Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) pathway by integrating chromatin immunoprecipitation sequencing, transcriptomic analyses, and CRISPR knockout screening, identifying the B-cell lineage factors POU2AF1 and ELL2, as crucial IL-6/JAK/STAT3 targets essential for MM cell growth and survival. Genetic depletion of these factors significantly suppressed MM cell growth in vitro and in the xenograft model of IL-6 humanized mice. Mechanistically, POU2AF1 and ELL2 form an autoregulatory loop with IRF4 and establish an MM-distinct transcriptional program representing cellular immaturity. The IL-6/JAK/STAT3 pathway augments this program by upregulating and recruiting these factors to MM signature genes. Furthermore, POU2AF1 and ELL2 are essential in the regulation of IL-6–dependent alternative RNA splicing. Immunocytochemical and proteomic analyses revealed that POU2AF1 colocalizes and facilitates formation of nuclear speckles, where it interacts with trans-acting splicing factors required for MM cell growth. These findings suggest dual roles of POU2AF1 and ELL2 in coordinating transcription and RNA splicing to generate MM-associated mRNA isoforms. Finally, we showed that gapmer antisense oligonucleotides targeting POU2AF1 reduced MM cell growth in the presence of soluble BM stromal cell factors, including IL-6. Our data demonstrate that IL-6–driven B-cell lineage factors are the vulnerability of MM cells and may represent novel therapeutic targets for this incurable tumor.